animal and human lives. In both human and veterinary medicine, the over-prescription of broadspectrum antiparasitic drugs; multiplies our need for new treatment methods. Numerous studies have demonstrated that MSC cells perform a paracrine function in tissue remodeling and controlling inflammation. The most recent pre-clinical findings in the use of MSCs as a treatment for parasitic infections were investigated in the present study. Methods: Nine databases (PubMed, Scopus, Google Scholar, Cochrane Library, Magiran, SID, Medline, Embase, and Lilacs) were searched for published articles on Anti-inflammatory and Immunomodulatory effects of Mesenchymal Stem Cell therapy on parasitic drug resistance from January 2000 to January 2023. Twenty affiliated articles with complete abstracts were included in this study. All data were extracted from interconnected papers and analyzed with R version 4.2.1 artificial intelligence software. Results: According to studies, administering MSCs to patients with parasitic infections such as schistosomiasis, malaria, cystic echinococcosis, toxoplasmosis, leishmaniasis, and trypanosomiasis decreases the parasite prevalence. MCSs modify the levels of pro- and antiinflammatory cytokines. Additionally, administering MSCs and anti-parasitic medications improved their anti-parasitic and immunomodulatory effects. In the parasitic diseases that cause liver injuries, it is shown that BM-MSCs transplantation could be worthwhile; because these stem cells can differentiate into hepatic cells, besides the enhancement of trophic intermediaries’ secretion capacity and immunomodulatory aspects. Conclusion: In conclusion, using MSCs with anti-parasitic medications enhanced anti-parasitic and immunomodulatory actions against parasitic diseases. The affordability of stem cell-based therapies will be crucial in their uptake, especially in underdeveloped nations where these neglected tropical diseases are a significant problem because these methodologies and techniques are still in their infancy.

Keywords